SND209

SND209 is a preclinical **small-molecule flavonoid derivative** reported as a research antineoplastic compound evaluated in human lymphoma models, particularly the SUDHL6 diffuse large B-cell lymphoma xenograft system. Publicly available context indicates that it showed **antiproliferative and proapoptotic activity** at nanomolar concentrations and achieved efficacy comparable to or greater than paclitaxel and doxorubicin at lower tested concentrations in that model. However, no validated public information was identified establishing a precise molecular target, formal mechanism of action, developer, manufacturer, clinical development program, regulatory status, or approved indication for SND209 specifically; it should therefore be regarded as an early preclinical research compound with incompletely characterized pharmacology in the public domain.